A phase 2, open-label, two-stage study of volociximab (M200) for the treatment of subjects with metastatic melanoma.

Trial Profile

A phase 2, open-label, two-stage study of volociximab (M200) for the treatment of subjects with metastatic melanoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Volociximab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 26 Apr 2012 Additional lead trial investigator (Mihail Obrocea) identified as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Company (Abbott) added to the associations field as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Actual patient number is 19 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top